Targeting and killing glioblastoma with monoclonal antibody to
O-acetyl GD2 ganglioside

Julien Fleurence; Denis Cochonneau; Sophie Fougeray; Lisa Oliver; Fanny Geraldo; Mickaël Terme; Mylène Dorvillius; Delphine Loussouarn; François Vallette; Francois Paris; Stéphane Birklé

Journal articles

Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside

Julien Fleurence ¹ Denis Cochonneau ² Sophie Fougeray ^{1, 3} Lisa Oliver ¹ Fanny Geraldo ¹ Mickaël Terme ² Mylène Dorvillius ² Delphine Loussouarn ¹ François Vallette ^{4, 1} Francois Paris ^{1, 4} Stéphane Birklé ^{1, 3, *}

* Corresponding author

1 CRCNA - Centre de Recherche en Cancérologie Nantes-Angers

2 OGD2 Pharma

3 UFR des Sciences Pharmaceutiques et Biologiques

4 LaBCT

Abstract : There are still unmet medical needs in the treatment of glioblastoma, the most common and the most aggressive glioma of all brain tumors. Here, we found that O-acetyl GD2 is expressed in surgically resected human glioblastoma tissue. In addition, we demonstrated that 8B6 monoclonal antibody specific for O-acetylat GD2 could effectively inhibit glioblastoma cell proliferation in vitro and in vivo. Taken together, these results indicate that O-acetylated GD2 represents a novel antigen for immunotherapeutic-based treatment of high-grade gliomas.

Document type :

Journal articles

Domain :

Life Sciences [q-bio] / Cancer

Complete list of metadatas

Cited literature [25 references] Display Hide Download

https://www.hal.inserm.fr/inserm-01319327
Contributor : Elizabeth Bernardo <>
Submitted on : Friday, May 20, 2016 - 4:05:23 PM
Last modification on : Friday, June 19, 2020 - 3:08:46 AM

Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside

File

Identifiers

Collections

Citation

Export

Metrics

290

183

Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside

File

Identifiers

Collections

Citation

Export

Share

Metrics

290

183